Meera Mohan

1.5k total citations
88 papers, 541 citations indexed

About

Meera Mohan is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Meera Mohan has authored 88 papers receiving a total of 541 indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Hematology, 48 papers in Oncology and 35 papers in Molecular Biology. Recurrent topics in Meera Mohan's work include Multiple Myeloma Research and Treatments (58 papers), CAR-T cell therapy research (21 papers) and Protein Degradation and Inhibitors (19 papers). Meera Mohan is often cited by papers focused on Multiple Myeloma Research and Treatments (58 papers), CAR-T cell therapy research (21 papers) and Protein Degradation and Inhibitors (19 papers). Meera Mohan collaborates with scholars based in United States, India and Canada. Meera Mohan's co-authors include Binod Dhakal, Anita D’Souza, Faith E. Davies, Carolina Schinke, Aasiya Matin, Parameswaran Hari, Frits van Rhee, Saurabh Chhabra, Maurizio Zangari and Sharmilan Thanendrarajan and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Meera Mohan

75 papers receiving 533 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Meera Mohan United States 12 342 293 264 69 61 88 541
Anjana Gupta United States 10 237 0.7× 428 1.5× 276 1.0× 65 0.9× 128 2.1× 16 789
Xing-Mei Cao China 11 179 0.5× 218 0.7× 191 0.7× 43 0.6× 188 3.1× 33 509
Heidi Mills United States 8 231 0.7× 346 1.2× 156 0.6× 30 0.4× 326 5.3× 20 563
Haodong Cai China 10 94 0.3× 182 0.6× 162 0.6× 18 0.3× 70 1.1× 28 421
Siv Helen Moen Norway 12 111 0.3× 129 0.4× 196 0.7× 30 0.4× 247 4.0× 17 483
Nathan D. Mathewson United States 15 186 0.5× 240 0.8× 398 1.5× 16 0.2× 372 6.1× 33 805
Jeonghwan Youk South Korea 12 93 0.3× 162 0.6× 240 0.9× 16 0.2× 34 0.6× 40 506
H. Pandha United Kingdom 12 159 0.5× 266 0.9× 218 0.8× 16 0.2× 99 1.6× 26 548
Xingbing Wang China 11 160 0.5× 306 1.0× 160 0.6× 17 0.2× 230 3.8× 56 604

Countries citing papers authored by Meera Mohan

Since Specialization
Citations

This map shows the geographic impact of Meera Mohan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Meera Mohan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Meera Mohan more than expected).

Fields of papers citing papers by Meera Mohan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Meera Mohan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Meera Mohan. The network helps show where Meera Mohan may publish in the future.

Co-authorship network of co-authors of Meera Mohan

This figure shows the co-authorship network connecting the top 25 collaborators of Meera Mohan. A scholar is included among the top collaborators of Meera Mohan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Meera Mohan. Meera Mohan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hadidi, Samer Al, et al.. (2025). Bispecific antibody therapy in CNS myeloma: Early evidence from a multicentre cohort. British Journal of Haematology. 207(5). 2161–2166.
2.
Banerjee, Rahul, Meera Mohan, Kai Rejeski, et al.. (2025). Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels. Blood Advances. 9(18). 4720–4726. 2 indexed citations
3.
Nyati, Kishan Kumar, Tarang Sharma, Binod Dhakal, et al.. (2024). CD47-CD138 Bispecific Antibody Exhibits Selective Targeting of Multiple Myeloma. Blood. 144(Supplement 1). 4812–4812. 1 indexed citations
4.
Patel, Krina K., Meera Mohan, Sundar Jagannath, et al.. (2024). Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma. PubMed. 1(4). 100043–100043.
5.
Furqan, Fateeha, Binod Dhakal, Timothy S. Fenske, et al.. (2024). Outpatient administration of CAR T-cell therapies using a strategy of no remote monitoring and early CRS intervention. Blood Advances. 8(16). 4320–4329. 5 indexed citations
6.
Kim, Soyoung, Binod Dhakal, Ayesha Aijaz, et al.. (2024). Outcomes of frail patients undergoing high‐dose chemotherapy and autologous stem cell transplantation for multiple myeloma. British Journal of Haematology. 205(6). 2370–2375.
7.
Akhtar, Othman Salim, Kwang Woo Ahn, Anita D’Souza, et al.. (2024). Comparison of Thiotepa-based Conditioning Regimens for Older Adults with Primary Diffuse Large B-cell Lymphoma of the Central Nervous System Undergoing Autologous Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy. 30(12). 1191.e1–1191.e8. 1 indexed citations
8.
Schmidt, Timothy M., Rafaël Fonseca, Rajshekhar Chakraborty, et al.. (2024). Alterations in chromosome 1q in multiple myeloma randomized clinical trials: a systematic review. Blood Cancer Journal. 14(1). 20–20. 10 indexed citations
9.
Chhabra, Saurabh, James H. Jerkins, Kathleen Monahan, et al.. (2024). Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation. 59(3). 373–379. 4 indexed citations
10.
11.
Portuguese, Andrew J., Rahul Banerjee, Anikó Szabó, et al.. (2023). Chimeric antigen receptor and bispecific T‐cell engager therapies in multiple myeloma patients with prior allogeneic transplantation. British Journal of Haematology. 204(3). 887–891. 3 indexed citations
12.
Dong, Jing, Emma Garacci, Anita D’Souza, et al.. (2022). Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study. Blood Cancer Journal. 12(2). 34–34. 25 indexed citations
13.
Mohan, Meera, Binod Dhakal, Sabarinath Venniyil Radhakrishnan, et al.. (2021). Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma. Blood Advances. 6(8). 2466–2470. 34 indexed citations
14.
Mohan, Meera, Anikó Szabó, Sharmilan Thanendrarajan, et al.. (2021). Persistent bone marrow minimal residual disease as a “high‐risk” disease feature in multiple myeloma. American Journal of Hematology. 96(9). E341–E344. 2 indexed citations
15.
Abdallah, Al‐Ola, Ghulam Rehman Mohyuddin, Nausheen Ahmed, et al.. (2021). Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease. SHILAP Revista de lepidopterología. 2(4). 757–764. 4 indexed citations
16.
Mohan, Meera, Samantha Kendrick, Anikó Szabó, et al.. (2021). Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma. Blood Advances. 6(3). 808–817. 18 indexed citations
17.
Jenjaroenpun, Piroon, Thidathip Wongsurawat, Zulema Udaondo, et al.. (2020). Complete Genome Sequences of Four Isolates of Vancomycin-Resistant Enterococcus faecium with the vanA Gene and Two Daptomycin Resistance Mutations, Obtained from Two Inpatients with Prolonged Bacteremia. Microbiology Resource Announcements. 9(6). 6 indexed citations
18.
Udaondo, Zulema, Piroon Jenjaroenpun, Thidathip Wongsurawat, et al.. (2020). Two Cases of Vancomycin-Resistant Enterococcus faecium Bacteremia With Development of Daptomycin-Resistant Phenotype and its Detection Using Oxford Nanopore Sequencing. Open Forum Infectious Diseases. 7(6). ofaa180–ofaa180. 9 indexed citations
19.
Mohan, Meera, Mary E. Meek, Katie Stone, et al.. (2018). Treatment of Unresectable Unicentric Castleman Disease with Therapeutic Embolization. Blood. 132(Supplement 1). 2415–2415. 1 indexed citations
20.
Thanendrarajan, Sharmilan, Carolina Schinke, Frits van Rhee, et al.. (2017). Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma. Blood. 130. 1858–1858. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anjana Gupta Breakdown of academic impact, for papers by Xing-Mei Cao Breakdown of academic impact, for papers by Heidi Mills Breakdown of academic impact, for papers by Haodong Cai Breakdown of academic impact, for papers by Siv Helen Moen Breakdown of academic impact, for papers by Nathan D. Mathewson Breakdown of academic impact, for papers by Jeonghwan Youk Breakdown of academic impact, for papers by H. Pandha Breakdown of academic impact, for papers by Xingbing Wang
Rankless by CCL
2026